FY2025 · ended Dec 31, 2025 · Revenue $30.91M, +36.8% YoY · Filed Mar 11, 2026
Foghorn Therapeutics Inc. (FHTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $30.9 million and a net loss of $74.3 million. Free cash flow was -$86.1 million. As of Jun 30, 2026 it held $167.6 million in cash and investments and $43.1 million in total debt.
Revenue (TTM)
$36.74M
+52.0% vs year-ago TTM
Net income (TTM)
$-64.58M
+14.3% vs year-ago TTM
Operating cash flow (TTM)
$-84.24M
+6.9% vs year-ago TTM
Free cash flow (TTM)
$-84.29M
+7.7% vs year-ago TTM
EPS (TTM)
$-0.97
+19.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
58.70M
+5.6% vs prior year
Net cash
$124.48M
as of Jun 30, 2026
Operating margin
-198.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FHTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1822462
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M |
| Diluted EPS | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 |
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.2M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M |
| Stockholders' equity | -$108.5M | -$45.5M | -$77.2M | $112,000 | $96.9M |
| Cash and investments | $158.9M | $243.7M | $234.1M | $345.8M | $154.3M |
| Total debt | $41.3M | $37.1M | $45.1M | $51.5M | $58.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Oct 1, 2026 | Sep 25, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 7, 2026 | May 7, 2026 |
All 354 Foghorn Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.